Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 46

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 46
---
 quantitative and qualitative corporate responsibility and sustainability disclosures are accurate and consistent. Each of these committees reports to the full Board on various corporate responsibility-related matters. In addition, we have leaders from across our organization, including human resources, commercial and laboratory operations, accounting, technology, compliance, legal, and communications, who are actively involved in, and advise on, corporate responsibility matters.

29

Executive and Director Compensation

Compensation Discussion and Analysis Executive Summary Overview We are a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. We develop and offer molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Our molecular tests provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Our compensation program is designed to support our mission and business strategy, with the primary objectives of attracting and retaining executive talent, motivating our executive officers through pay-for-performance metrics to enhance our growth and profitability, and increasing long-term stockholder value. This proxy statement reports on compensation paid or accrued during the year ended December 31, 2024 (the "fiscal year 2024" or "2024 fiscal year") and certain elements of compensation to be paid under our fiscal year 2025 compensation program. Our named executive officers ("NEOs") for the 2024 fiscal year are:

| Name               |     | Title                                    |
| Paul J. Diaz       |     | President and Chief Executive Officer(1) |
| Scott J. Leffler   |     | Chief Financial Officer(2)               |
| R. Bryan Riggsbee  |     | Former Chief Financial Officer(3)        |
| Samraat S. Raha    |     | Chief Operating Officer(4)               |
| Mark S. Verratti   |     | Chief Commercial Officer(5)              |
| Dale Muzzey, Ph.D. |     | Chief Scientific Officer                 |

(1) Mr. Diaz announced that he will resign from his position as President and Chief Executive Officer effective April 30, 2025. (2) Mr. Leffler was appointed Chief Financial Officer effective January 29, 2024. (3) Mr. Riggsbee resigned from his position as Chief Financial Officer effective January 29, 2024. (4) Mr. Raha will succeed Mr. Diaz as President and Chief Executive Officer effective